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Cytochrome P17 Inhibition With Ketoconazole
As Treatment for Advanced Granulosa Cell
Ovarian Tumor
Case Report
A 37-year-old woman who was an active smoker with no other
medical conditions andnopreviouspregnancieswasdiagnosedwith a
granulosa cell tumor of the left ovary in June 2002. A laparoscopic
partial adnexectomy was performed in a local institution without
completion of surgical stadification. In January 2006, an ipsilateral
ovarian recurrence was detected. An open laparotomymass resection
plus contralateral adnexectomy, hysterectomy, pelvic and paraortic
lymphadenectomy, and peritoneal sampling were performed. The
anatomopathologic diagnosis was ovarian granulosa tumor, Interna-
tional FederationofGynecology andObstetrics stage IC,with a length
of 10 cm and weight of 121 g. Adjuvant chemotherapy with a combi-
nationof cisplatin, etoposide, andbleomycin (BEP)was administered
for three cycles. By January 2009, a unique peritoneal recurrence close
to the spleen, 6 cmin length,wasdetectedand resected.Three cyclesof
BEP were again administered.
On follow-up in February 2011, three peritoneal implants were
found and resected without adjuvant treatment. Six months later, a
newperitoneal recurrencenear the liverwasdiagnosed, (Fig 1, arrow).
No hormonal overproduction (neither estrogen nor androgens) was
detected along the disease. Although inhibins have been proposed as
serum markers for this tumor, their usefulness when guiding thera-
peutic decisions remains controversial and has not been studied.1
A genetic analysis was performed of the tumor that had been
resected in2006, identifying theFOXL2Cys134Trp (c.402CG;Fig 2,
arrow) mutation, which is patognomonic for granulosa cell tumors.
Because of the short disease-free interval, resection was no longer
considered an option. On the basis of the molecular consequences of
suchmutations, asdescribed in the literature,ketoconazoleat adoseof
400 mg three times per day plus hydrocortisone was offered. After
signing written consent, the patient initiated treatment in August
2011. Tenmoths later, she has not experienced progression and con-
tinues to receive ketoconazole.
Discussion
Granulosa cell tumors are a rare disease with only 0.4 to 1.2 new
cases per 100,000 inhabitants per year.2 Hormonal production by the
tumor (estrogens, progesterone, or androgens) can lead to some typ-
ical manifestations such as hypermenorrhea, galactorrhea, or hirsut-
ism. Recurrences have been documented up to 10 years after
first resection.
Two phase II clinical trials published in 1999 by the Gynecologic
OncologyGroup(GOG)and theEuropeanOrganisation forResearch
and Treatment of Cancer, respectively, established platinum-based
combinations (BEP or cisplatin, vinblastine, and bleomycin) as the
cornerstone of systemic treatment.3,4 Although partial responseswere
achieved in up to 60%of patients,metastatic disease continues to be a
lethal condition. Currently, GOG is comparing BEP versus paclitaxel
and carboplatin in a clinical trial (GOG 187).5
Interestingly, different hormone therapies, such as me-
droxyprogesterone or gonadotropin-releasing hormone ago-
nists, have sporadically been tested.6-9 In 1996, Fishman et al10
treated six patients with leuprolide and achieved two partial
remissions and three stabilizations.
In 2009, Shah et al11 found, through whole-transcriptome anal-
ysis, amutation in theFOXL2 gene (c.402CG[C134W]) that is now
considered patognomonic of granulosa cell tumors. FOXL2 is a
forkhead–winged helix transcription factor that is involved in granu-
losa cell development and is part of the complex AP1-Smad3-Smad4,
which activates the expression of the gonadotropin-releasing hor-
mone receptor at hipophysis.
Interestingly, the FOXL2 protein physiologically downregulates
cytochrome P17 (CYP17), the enzyme that is responsible for the
conversion of 17-hydroprogesterone to androstenedione. Thus, the
pathologic FOXL2 mutation (402CG [C134W]) could potentially
lead to higher levels of this protein and consequently to a rise in
androstenedione levels.12
Because ketoconazole is a well-characterized CYP17 inhibitor,
we decided to offer the patient such treatment after multiple recur-
rences, resections, and adjuvant treatments.13 The patient is doing
well,withoutprogression.This encouraging experience and itsmolec-
ular rationalehave led theSpanishGroup inOrphanandRareTumors
(GETHI) to design a clinical trial (Granulosa et Ketoconazole, or
GREKO) that will test the role of CYP17 inhibition in this tumor. If
positive,multiple targeteddrugs that are focusedonthis enzymecould
easily come into the field for the treatment of this rare condition.Fig 1.
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